Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
This feature explores evolving management strategies for bone sarcomas, highlighting multidisciplinary treatment approaches ...
Health experts have underlined that soft tissue sarcomas, a rare and complex group of cancers, require precise diagnosis, ...
Natera NTRA announced that its molecular residual disease (MRD) test, Signatera, received certification as a Class C device ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
An analysis from the FLEX study showed that only patients in MammaPrint's highest risk category benefitted from the addition ...
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
Older patients represent the fastest growing patient group in clinical care. They are a heterogeneous group, for whom evidence for making treatment decisions is often scarce. Important domains for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results